Study on the Safety and Effectiveness of Lete-Cel for Treating Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Inclusion Criteria

• Must be at least 10 years old.
• Must weigh at least 40 kg if receiving the study drug.
• Must have specific genetic markers (HLA-A02:01, HLA-A02:05, and/or HLA-A*02:06).
• Tumor must test positive for NY-ESO-1.
• Must have a diagnosis of synovial sarcoma or myxoid/round cell liposarcoma.
• Must be in good general health with a performance status score above 60.
• Must have adequate organ function and blood cell counts before starting treatment.
• Must have measurable disease according to specific criteria.
• Must agree to use contraception during the study.
• Must meet specific health history requirements.

Exclusion Criteria

• Cancer has spread to the brain or spinal cord.
• Have another type of cancer that is not in complete remission.
• Have a serious illness that could interfere with the study treatment.
• Have a history of certain diseases affecting the nervous system.
• Have a history of severe autoimmune diseases requiring treatment.
• Have received previous treatments targeting NY-ESO-1.
• Have had gene therapy or a stem cell transplant in the past.
• Must follow specific waiting periods after previous cancer treatments.
• Have had major surgery within 28 days before starting the study treatment.
• Have received too much radiation in the past.